LIFE:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund Hedged Units (CAD)

ETF | Sector Equity |

Last Closing

CAD 21.55

Change

-0.08 (-0.37)%

Market Cap

CAD 0.21B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for Sector Equity

Symbol Name Price(Change) Market Cap
TEC:CA TD Global Technology Leaders I..

-0.37 (-0.92%)

CAD 2.91B
ZWU:CA BMO Covered Call Utilities ETF

-0.14 (-1.21%)

CAD 1.92B
TXF:CA First Asset Tech Giants Covere..

-0.19 (-0.87%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

-0.54 (-0.92%)

CAD 0.65B
XHC:CA iShares Global Healthcare (CAD..

-0.18 (-0.24%)

CAD 0.64B
HTA:CA Harvest Tech Achievers Growth ..

-0.16 (-0.85%)

CAD 0.63B
ZUT:CA BMO Equal Weight Utilities Ind..

-0.33 (-1.47%)

CAD 0.45B
CWW:CA iShares Global Water Common Cl..

-0.12 (-0.20%)

CAD 0.34B
XUT:CA iShares S&P/TSX Capped Utiliti..

-0.47 (-1.67%)

CAD 0.30B
COW:CA iShares Global Agriculture Com..

+0.04 (+0.06%)

CAD 0.29B

ETFs Containing LIFE:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Sector Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.66% 26% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.66% 26% F 31% F
Trailing 12 Months  
Capital Gain 4.97% 14% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.97% 14% F 22% F
Trailing 5 Years  
Capital Gain 10.91% 20% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.91% 20% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.21B 62% D 47% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.